EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy

Thi Thom Tran, Thi Tu Uyen Phan, Michael Baboudjian, Quang Hieu Duong, Ines Sousa, Thi Thuy Le, Virginie Baylot, Sophie Giusiano, Laurent Daniel, Pauline Brige, Benjamin Guillet, Cyrille Bastide und 4 weitere

Advanced Healthcare Materials · 2026-11 · 15 (41)

DOI: 10.1002/adhm.202505251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 11.10.2026. Verfasst von Thi Thom Tran und 15 weiteren Autor:innen. Beteiligte Einrichtung: INSERM ERL U1326, CINaM, CERIMED, CNRS UMR 7325, Aix-Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Organoids, Prostatic Neoplasms, Oligonucleotides, Antisense, Precision Medicine. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ligue Nationale Contre Le Cancer, ITMO cancer, Fondation de France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient‐derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with high target specificity, yet their application in organoid systems remains underexplored. Here, we adapted previously described protocols to establish a biobank of prostate cancer (PC) PDOs, achieving a high initial growth success rate (>90%). Histological and molecular analyses confirmed the preservation of key tumor features. Using these models, we assessed several ASOs, with particular emphasis on OGX‐427 (Apatorsen), an ASO targeting heat shock protein 27 (HSP27) that has been evaluated in phase I/II clinical trials. While OGX‐427 effectively suppressed HSP27 expression and inhibited cell growth in 2D cultures, its efficacy was markedly limited in 3D organoids, likely due to extracellular matrix and structural barriers. Removing Matrigel and applying single‐cell transfection overcame these barriers, achieving efficient ASO uptake, significant target protein downregulation, and robust, dose‐dependent inhibition of organoid growth. These findings underscore the utility of PDOs for evaluating ASO‐based therapies and their potential to accelerate precision oncology strategies for PC and other malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsProstatic NeoplasmsOligonucleotides, AntisensePrecision MedicineHumansMaleHSP27 Heat-Shock ProteinsMolecular ChaperonesCell Line, TumorCell ProliferationHeat-Shock Proteins

Stichwörter der Autor:innen

antisense oligonucleotides (ASOs)apatorsen (OGX‐427)heat shock protein 27 (HSP27)mRNA targetingpatient‐derived organoids (PDOs)precision medicineprostate cancer (PC)

Substanzen

Oligonucleotides, AntisenseHSP27 Heat-Shock ProteinsMolecular ChaperonesHSPB1 protein, humanHeat-Shock Proteins

Autor:innen und Institutionen

  • INSERM ERL U1326, CINaM, CERIMED, CNRS UMR 7325, Aix-Marseille University, Marseille, France.
  • Department of Urology, Hospital Nord, AP-HM, Aix-Marseille University, Marseille, France.
  • Laboratoire d'Anatomie et Cytologie Pathologiques, Hôpital de la Timone, AP-HM, Marseille, France.
  • European Center for Research in Medical Imaging (CERIMED), Aix-Marseille University, Marseille, France.
  • University of Burgundy Europe, INSERM UMR 1231, HSP-Pathies, Centre for Translational and Molecular Medicine, Dijon, France.
  • University of Burgundy Europe, Centre Georges-François Leclerc (CGFL), Dijon, France.

ORCID-Profile: Thi Khanh Le, Palma Rocchi

Förderung

  • Ligue Nationale Contre Le Cancer
  • ITMO cancer
  • Fondation de France
  • Amidex Excellence Initiative, Imaging Institute
  • French Excellence Scholarship

Zitieren

APA

Tran, T. T., Phan, T. T. U., Baboudjian, M., Duong, Q. H., Sousa, I., Le, T. T., Baylot, V., Giusiano, S., Daniel, L., Brige, P., Guillet, B., Bastide, C., Garrido, C., Taïeb, D., Le, T. K., & Rocchi, P. (2026). Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy. Advanced Healthcare Materials, 15(41). https://doi.org/10.1002/adhm.202505251

Vancouver

Tran TT, Phan TTU, Baboudjian M, Duong QH, Sousa I, Le TT, et al. Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy. Advanced Healthcare Materials. 2026;15(41). doi:10.1002/adhm.202505251

BibTeX
@article{Tran2026,
  author = {Tran, Thi Thom and Phan, Thi Tu Uyen and Baboudjian, Michael and Duong, Quang Hieu and Sousa, Ines and Le, Thi Thuy and Baylot, Virginie and Giusiano, Sophie and Daniel, Laurent and Brige, Pauline and Guillet, Benjamin and Bastide, Cyrille and Garrido, Carmen and Taïeb, David and Le, Thi Khanh and Rocchi, Palma},
  title = {Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  volume = {15},
  number = {41},
  doi = {10.1002/adhm.202505251}
}
Kostenlos starten →